Cost-effectiveness analysis of implementing polygenic risk score in a workplace cardiovascular disease prevention program
Risk of Coronary Artery Disease Conferred by Low-Density Lipoprotein Cholesterol Depends on Polygenic Background
Integrating a Polygenic Risk Score for Coronary Artery Disease as a RiskEnhancing Factor in the Pooled Cohort Equation: A Cost-Effectiveness Analysis Study
Polygenic Risk Scores in Clinical Care Filling the Gap in Risk Assessments for Common Diseases
Development and Validation of a Polygenic Risk Score for Coronary Artery Disease
Genetic assessments of breast cancer risk that do not account for polygenic background are incomplete and lead to incorrect preventative strategies
Development and Validation of Multi-Ancestry Polygenic Risk Scores for Coronary Artery Disease
This document outlines an approach for using a Polygenic Risk Score (PRS) in a Coronary Artery Disease (CAD) clinical pathway.
This document outlines an approach for using a Polygenic Risk Score (PRS) in a breast cancer clinical pathway.
Allelica - Introduction to Polygenic Risk Score
The PREDICT module equips genetics laboratories with a trusted software as a medical device for ancestry-informed PRS analysis and clinical-grade reporting.
Lord Darzi’s Independent investigation of the NHS in England
A how-to guide for how to use breast cancer polygenic risk scores
Atherosclerotic Cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide.
Polygenic Risk Scores (PRS) are a powerful tool in precision medicine, offering insights into an individual’s genetic predisposition to various diseases.
Polygenic risk scores (PRS) predict the likelihood of developing complex diseases based on an individual’s genetic makeup. However, their application across different genetic ancestries presents numerous challenges.
Allelica builds software that enables clinical genetics labs and health systems to deploy robust and accurate Polygenic Risk Scores (PRS), at scale. But what is a PRS?
Allelica, Inc’s risk reports align with disease specific guidelines to communicate an individual’s risk of disease based on their PRS. Risk can be communicated as relative or absolute...
Randomized clinical trials are the gold standard approach for testing the efficacy and safety of novel therapeutics in real world populations and are essential for bringing drugs safely to market. However, a number of variables make clinical trials...
As Allelica continues to work toward enhancing accessible data-driven healthcare, we are proud to announce a collaboration with Labcorp to ensure polygenic and monogenic risk factors are assessed and accounted for in the patient journey...
The publication of the updated Global Burden of Disease (GBD) Reports is a timely reminder of the many different diseases that affect the global population. With somewhat morbid curiosity, it’s fascinating to...
The evidence is undeniable — polygenic risk score (PRS) testing enables healthcare providers to identify more high risk patients at an earlier stage, leading to better risk management and improved outcomes...
We have previously reported how polygenic risk scores (PRS) can be used to identify people at high genetic risk of disease, paving the way for their use as tools for the prevention of common, chronic disease...
Much of the development of polygenic risk scores (PRSs) centers on assessing their ability to predict risk in different populations. This undoubtedly provides assurance of their clinical validity, which is a crucial component of PRS development...
Fast and scalable genome imputation of Low-Coverage WGS and Microarray data in just minutes. Allelica’s PRS pipeline is built around a set of interconnected modules…
Bringing a new medical test to market requires generating and compiling a range of evidence. A commonly used framework for evaluating novel genetic tests involves describing an assessment of three main aspects of the test: its analytical validity,...
In today’s fast-paced corporate landscape, the health and well-being of employees are paramount for sustained productivity and success. One of the most prevalent health challenges facing workplaces is cardiovascular disease, particularly...
In the fast-paced world of business, ensuring the well-being of employees has become a top priority for innovative employers. A successful wellness program not only fosters a culture of healthier and happier employees, but also yields impressive returns...
Maintaining a healthy and engaged workforce is a cornerstone of a successful organization. Workplace health programs not only enhance the well-being of employees but also contribute to increased productivity, reduced absenteeism, and...
Cardiovascular diseases — a general term for a suite of diseases that affect the heart or blood vessels — account for one in three deaths globally and are a major drain on public health spending. Our risk of cardiovascular disease increases as we age...
Clinical trials are an essential part of the pharmaceutical industry, but they face many challenges. One of the significant obstacles is the high rate of failure, with over 90% of drug candidates that...
A valid question that is often asked when discussing PRS implementation is “how will this information be used in clinical care in the absence of clinical guidelines for PRS”? One approach is to ensure PRS risk information is presented in a way that...
This year was kicked off by the publication of the NSGC Practice Resource for Clinical Counseling/Translation of Polygenic Scores, put together by Wand et al. — a stellar team of leaders in the PRS field.
We’ve previously written about how you can use Allelica’s DISCOVER software to build new polygenic risk scores (PRS) and to deploy them at scale with PREDICT. While a PRS provides…
This week, scientists from the Clinical Genome Resource (ClinGen) Complex Disease Working Group and the Polygenic Score (PGS) Catalog published a paper in Nature introducing…
Cardiovascular disease is the leading cause of death worldwide, with recent estimates putting the global death toll at around 18 million each year. It is also a major burden on populations and health systems, contributing to…
In our previous articles on Allelica’s PRS pipeline, we ran through how you can use our DISCOVER module to build your own PRS for a disease or trait of interest, as well as how our VALIDATE module can be used to test the predictive power of…
Essential testing of your PRS on an independent population. In our previous articles outlining Allelica’s PRS pipeline we described how users can impute genotype or…
A user friendly, cloud-based computing solution to build state-of-the-art, publication ready polygenic risk scores. The DISCOVER moduleallows users to build their own polygenic risk…
Within the last two decades, and upon completion of the world’s largest biological project in 2003, interest in the human genome and its effect on…
We previously wrote about the enormous impact that the UK Biobank (UKBB) is having to translational research. Although the scientific outputs from this project are now beginning…
In Allelica we’re very excited about the incredible advances that analyses of large DNA datasets are bringing to medicine. In addition to the increasingly…
Vast quantities of human DNA have been sequenced for biomedical research and clinicians, researchers and innovators are now beginning to focus on the next phase of the genomic revolution: translating these data into tools...
In the late 19th Century, a Moravian monk named Gregor Mendel passed his time by running experiments cross-breeding different types of pea plant. Amongst his…
A central goal of preventative medicine is to identify the people most at risk of disease early enough that something can be done…
Allelica announces the release of the Allelica Precision Server for CLIA-compliant, on-premises analysis and clinical reporting of polygenic risk score, pharmacogenomics and carrier screening
UAB Cardiogenomics Clinic and Allelica to perform polygenic risk score clinical implementation study
Allelica Launches Ancestry-Specific Polygenic Risk Score Tests for Common Diseases as a Laboratory-Developed Test
Allelica's Health Economics Study Demonstrates Cost Savings of Polygenic Risk Score in Heart Attack Prevention
Allelica Collaborates with Invitae to Build Ancestry-Informed Polygenic Risk Score for Breast Cancer
Allelica Joins Forces with Leader in Genotyping Technology to Enable Polygenic Risk Score
Yale School of Medicine Researcher Selects Allelica to Expand Polygenic Risk Score Research on Childhood Neuropsychiatric Disorders